Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
antibody drugs
Biotech
Sino Biopharm buys Merck’s PD-1xVEGF bispecific partner LaNova
LaNova's PD-1xVEGF bispecific antibody was licensed to Merck in a $588 million upfront deal.
Angus Liu
Jul 15, 2025 10:16am
Biocon accused of IP theft to create cancer biotech Bicara
Oct 24, 2024 11:04am
AstraZeneca preps new COVID push after antibody's ph. 3 success
May 16, 2024 7:15am
Charles River Labs partners with Wheeler Bio for CMC platform
Feb 26, 2024 3:15pm
Disco gets down with €20M to find targets for cancer therapy
Jan 16, 2024 3:30am
GSK gives early look at HIV bNAb's power
Oct 25, 2022 10:00am